Rosetta and Moffitt Enter into Agreement to Develop Thyroid Neoplasia Assay
Jun 27 14
Rosetta Genomics Ltd. and Moffitt Cancer Center have entered into an agreement for the development and commercialization of Rosetta's thyroid neoplasia assay. Under the agreement, Rosetta will work with Marino Leon, associate member of the Department of Anatomic Pathology at Moffitt. A fine needle aspiration (FNA), a non-surgical procedure used to obtain tissue for analysis by a pathologist, is the standard technique for detecting cancer.
Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Cente and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Form Cancer Research Collaboration for Big Data
May 28 14
Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Cente and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), announced a collaboration to accelerate discoveries in cancer research. Named the Oncology Research Information Exchange Network (ORIEN), the new partnership will launch with over 100,000 consented patients who have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level. ORIEN will utilize a single protocol, Total Cancer Care(R), to create a collaborative, "rapid learning" environment that will share de-identified data to accelerate the development of targeted treatments, allowing researchers and clinicians to more quickly match eligible patients to clinical trials and conduct larger and richer analysis. Through data analysis and sharing, ORIEN will provide physicians evidence of the best therapeutic options, including clinical trial treatments, specific to a patient's biological and epidemiological profile, increasing the likelihood of treatment efficacy, speeding response time, and potentially minimizing side effects while improving outcomes. ORIEN builds upon the strengths of its founders' National Cancer Institute-designated comprehensive cancer centers: Moffitt's Total Cancer Care protocol, biorepository and data warehouse of patients' genotypic and phenotypic data, and OSUCCC-James's depth and breadth in translating molecular- and genetic-based discoveries into more effective ways to prevent, detect, treat and ultimately cure cancers. M2Gen(R), a subsidiary of Moffitt, will serve as ORIEN's operational and commercial provider for support, bringing expertise in data management and informatics.
Moffitt Cancer Center Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 08:30 AM
Mar 12 14
Moffitt Cancer Center Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 08:30 AM. Venue: New York Academy of Sciences, New York, United States. Speakers: James Mule, Associate Center Director.